Omeros | OMER - Operating Expenses


Omeros reported $59.16M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Adma Biologics USD 76.41M 6.8M Dec/2025
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 172.75M 20.93M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Rockwell Medical USD 30.41M 1.11M Jun/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xoma USD 22.84M 1.67M Sep/2024